The 35% revenue growth, record system shipments, and 25% RPO expansion confirm accelerating adoption. With $58.6M cash and reiterated guidance implying 27-30% full-year growth, the stock should re-rate higher. Watch for FDA clearance for PTSD in MDD (Q2 2026 filing) as a major catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 13 $16.31entry
- T+1 · 6mo ago +0.06%α −0.72% · $16.32
- T+5 · 6mo ago −8.71%α −7.55% · $14.89
- T+20 · 5mo ago −9.93%α −9.32% · $14.69
- T+60 · 3mo ago −4.97%α −9.40% · $15.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrainsWay reported Q1 2026 revenue of $15.5M (+35% YoY) and net income of $2.3M (+107% YoY), both well above consensus estimates of $14.6M and $0.05 EPS. The company reiterated full-year 2026 guidance of $66-68M revenue and $12-14M Adjusted EBITDA, while shipping a record 117 Deep TMS systems and growing RPOs 25% to $75M.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $15.5M, +35% YoY vs $11.5M
- Net income $2.3M, +107% YoY vs $1.1M
- GAAP EPS $0.06 vs consensus $0.05 (beat)
- Adjusted EBITDA $2.8M, +117% YoY
- Record 117 Deep TMS systems shipped, +44% YoY
- RPOs $75M, +25% YoY
- Gross margin 75%, steady YoY
- Operating income $2.0M vs $0.6M YoY
- Cash and equivalents $58.6M
- Reiterated FY2026 guidance: revenue $66-68M, operating income 13-14%, Adjusted EBITDA $12-14M
- FDA submission planned for PTSD in MDD in Q2 2026
- First insurer coverage for accelerated SWIFT protocol secured
Financial Impact
Revenue beat by $0.9M (6.2%) vs $14.6M consensus; EPS $0.06 vs $0.05 consensus (20% beat); Adjusted EBITDA doubled to $2.8M
Risk Factors
- Reiterated guidance may be conservative given Q1 beat, any future miss would disappoint
- Investment in Neurolief ($11M total) and BrainStim ($1M) carry execution risk
- Dependence on expanding insurance coverage for continued growth
- Cash burn from investing activities ($9.3M in Q1) could pressure balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293884 |
Track record
24 reports on BWAY
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +27.55% at T+60 after the Mar 4, 2026 report. 7 of 10 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Bullish 6/10 No price data
- Nov 10, 20266d ago 6-K Neutral 5/10 Entry $10.67 Now $9.39 −12.00% settles Dec 9
- Nov 2, 202614d ago 6-K Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $11.09 Now $9.39 −15.33% settles Dec 1
- Oct 26, 202621d ago 6-K Neutral 3/10 Entry $11.21 Now $9.39 −16.24% settles Nov 23
- Oct 21, 202626d ago 6-K Neutral 3/10 Entry $11.44 Now $9.39 −17.92% settles Nov 19
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $11.99 to $9.39 Now $9.39 −21.68% ▼ −21.68% −18.22% vs SPY
- Oct 13, 20264w ago 6-K Neutral 4/10 Entry $11.92 to $10.67 Now $9.39 −21.22% ▼ −10.49% −6.88% vs SPY
- Sep 8, 20269w ago 6-K Neutral 4/10 Entry $14.16 to $11.89 Now $9.39 −33.69% ▼ −16.03% −18.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers